Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC

Lily announces positive gene therapy result for genetic hearing loss

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant

Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union

Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases

Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate

Servier and Base4 partner to advance neuroscience drug development

Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China

Innovent will supply sintilimab for the collaborated clinical trial

Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension

Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908

Progenesis opens genetic laboratory in New Delhi and AI & Bioinformatics data centre in Chennai

Leading USA based genetic testing brand officially enters the Indian market

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Roche expands hepatitis diagnostics portfolio

Almost 300 million people globally have chronic hepatitis B

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

LG Chem initiates phase 2 clinical trials in patients with defects in MC4R pathway causing obesity and hyperphagia

LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Zydus announces IND clearance of a novel Anti-PCSK9 candidate

Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity

Merck and Eisai update on Two Phase 3 Trials Evaluating Keytruda plus Lenima for cell lung cancer

The companies will work with investigators to share the results with the scientific community

BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development

The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases